This offer is only valid for patients with commercial insurance. Commercially insured patients whose insurance does not cover TARGRETIN will pay more. These savings offers are not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare, (including Medicare Advantage and Part A, B and D Plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. Void where prohibited by law, taxed or restricted. Cannot be redeemed at government-subsidized clinics. Valeant Pharmaceuticals reserves the right to rescind, revoke, or amend this offer without notice. You agree not to seek reimbursement for all or any part of the benefit received through this offer and are responsible for making any required reports of your use of this offer to any insurer or other third party who pays any part of the prescription filled. This offer is not valid for any person that is 65 years of age or older without commercial insurance. You must be 18 years of age or older to redeem this offer for yourself or a minor. You must present this coupon along with your prescription to participate in this program. You must activate this coupon before using by calling 1-888-201-1385 or visiting . Reimbursement limitations apply. Patient is responsible for all additional costs and expenses after reimbursement limits are reached. This coupon and offer are not health insurance.
Treatment of mantle cell lymphoma is difficult because patients usually are diagnosed in stage IV where the MCL has advanced throughout the body. There are many different therapeutic regimens to treat MCL; most include multiple chemotherapy drug administrations. Rituximab ( Rituxan ), in combination with other chemotherapy drugs , is typically used to treat patients who have MCL. Rituxan is a monoclonal antibody used to treat different cancers of the lymphoid cells. Newer chemotherapy drugs used for MCL include bortezomib ( Velcade ). Other treatments include stem cell transplantation and R-hyper-CVAD, a more intensive form of chemotherapy. Some patients may benefit from surgical debulking (removal of tissue to reduce symptoms). There is no cure for MCL; treatments are done to reduce symptoms and/or to increase limited survival time. Patients should speak with their physician team members to decide what treatment options are best.